Diagnosis and Management of Prolactinoma
Diagnostic Features
- Primary amenorrhea with galactorrhea in an adolescent female is pathognomonic for prolactinoma, as stated by the Endocrine Society guidelines 1
- A 2 cm sellar lesion with suprasellar extension and optic chiasm compression is consistent with a macroprolactinoma, according to the Endocrine Society guidelines 1
- The peripheral enhancement pattern on MRI is typical for prolactinoma, as noted by the Endocrine Society guidelines 1
- Initial prolactin levels of 255 ng/mL are appropriate for a 2 cm macroprolactinoma, as stated by the Endocrine Society guidelines 1
- A 75% reduction in prolactin levels after only 4 doses of cabergoline is highly specific for prolactinoma, as stated by the Endocrine Society guidelines 1, 2
Management and Treatment
- The Endocrine Society recommends continuing cabergoline with dose escalation as needed to target prolactin normalization and tumor shrinkage 1, 2
- The standard dose of cabergoline for macroprolactinomas is up to 2 mg/week, though some patients respond to lower doses, as stated by the Endocrine Society guidelines 1, 4
- If prolactin doesn't normalize with standard doses, the Endocrine Society recommends increasing the dose gradually to 3.5 mg/week, or up to 7 mg/week in exceptional cases 1, 4
- The Endocrine Society recommends monitoring prolactin levels in 1-3 months, then every 3-6 months until stable, and repeating MRI at 3-6 months to assess tumor shrinkage 1, 2
Recommended Monitoring Protocol
- The Endocrine Society recommends rechecking prolactin levels in 1-3 months, then every 3-6 months until stable 2, 3
- The Endocrine Society recommends repeating MRI at 3-6 months to assess tumor shrinkage 1, 2
- The Endocrine Society recommends monitoring for visual field improvement given the optic chiasm compression 1
- The Endocrine Society recommends baseline echocardiogram now, then every 5 years if dose remains ≤2 mg/week, or annually if dose exceeds 2 mg/week 2, 4